[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Peckys et al., 2021 - Google Patents

Quantification of EGFR-HER2 heterodimers in HER2-overexpressing breast cancer cells using liquid-phase electron microscopy

Peckys et al., 2021

View HTML
Document ID
10759973912087309593
Author
Peckys D
Gaa D
de Jonge N
Publication year
Publication venue
Cells

External Links

Snippet

Currently, breast cancer patients are classified uniquely according to the expression level of hormone receptors, and human epidermal growth factor receptor 2 (HER2). This coarse classification is insufficient to capture the phenotypic complexity and heterogeneity of the …
Continue reading at www.mdpi.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/543—Immunoassay; Biospecific binding assay with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications

Similar Documents

Publication Publication Date Title
Lin et al. Highly multiplexed imaging of single cells using a high-throughput cyclic immunofluorescence method
Stadler et al. Immunofluorescence and fluorescent-protein tagging show high correlation for protein localization in mammalian cells
De Wit et al. Classification of cells in CTC-enriched samples by advanced image analysis
Harwardt et al. Single-molecule super-resolution microscopy reveals heteromeric complexes of MET and EGFR upon ligand activation
He et al. Quantum dots-based immunofluorescent imaging of stromal fibroblasts Caveolin-1 and light chain 3B expression and identification of their clinical significance in human gastric cancer
Ilié et al. Chromogenic multiplex immunohistochemistry reveals modulation of the immune microenvironment associated with survival in elderly patients with lung adenocarcinoma
Chahoud et al. Prognostic significance of p16 and its relationship with human papillomavirus status in patients with penile squamous cell carcinoma: results of 5 years follow-up
de Muynck et al. Novel molecular targets for tumor-specific imaging of epithelial ovarian cancer metastases
Alvarenga et al. A comparison between manual and automated evaluations of tissue microarray patterns of protein expression
Peckys et al. Quantification of EGFR-HER2 heterodimers in HER2-overexpressing breast cancer cells using liquid-phase electron microscopy
Mäkinen et al. IGF2BP3 associates with proliferative phenotype and prognostic features in B-cell acute lymphoblastic leukemia
Cass et al. Automated quantitative analysis of p53, Cyclin D1, Ki67 and pERK expression in breast carcinoma does not differ from expert pathologist scoring and correlates with clinico-pathological characteristics
Vathiotis et al. Quantitative assessment of CD200 and CD200R expression in lung cancer
Gao et al. Proteomic tissue-based classifier for early prediction of prostate cancer progression
de Abreu Pereira et al. Proteomic Analysis of HCC-1954 and MCF-7 Cell Lines Highlights Crosstalk between αv and β1 Integrins, E-Cadherin and HER-2
Yin et al. MET expression level in lung adenocarcinoma loosely correlates with MET copy number gain/amplification and is a poor predictor of patient outcome
Cevenini et al. Secretome proteomic approaches for biomarker discovery: an update on colorectal cancer
Kim et al. Midkine and NANOG have similar immunohistochemical expression patterns and contribute equally to an adverse prognosis of oral squamous cell carcinoma
Asakage et al. Comprehensive gene analysis of IgG4-related ophthalmic disease using RNA sequencing
Zhou et al. A prediction model for ROS1-rearranged lung adenocarcinomas based on histologic features
Jütte et al. Krt20, krt5, esr1 and erbb2 expression can predict pathologic outcome in patients undergoing neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer
Kaufmann et al. Using the R package spatstat to assess inhibitory effects of microregional hypoxia on the infiltration of cancers of the head and neck region by cytotoxic T lymphocytes
Ecke et al. Prediction of response to cisplatin-based neoadjuvant chemotherapy of muscle-invasive bladder cancer patients by molecular subtyping including KRT and FGFR target gene assessment
Rantala et al. Expanding the diversity of imaging-based RNAi screen applications using cell spot microarrays
Lee et al. Correlation of yes-associated protein 1 with stroma type and tumor stiffness in hormone-receptor positive breast cancer